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ABSTRACT 
Introduction: Development of resistance to antimalarials has emerged as one of the greatest challenges facing malaria control 
today. In vitro drug sensitivity relies on the growth of plasmodium in the presence of the antimalarials. Any delay beyond 24 
hours in performing the assay results in decreased parasite viability and subsequent IC50 values. Fresh isolates brought in for assay 
from collection sites situated far from the laboratory require a medium to keep the parasites viable in order to produce results 
which more accurately reflect intrinsic antimalarial drug resistance. Objective: To evaluate the use of a formulated transport 
medium (TM) in maintaining the viability of plasmodium during storage at 40C against a panel of antimalarials, compared to the 
conventional EDTA anticoagulant. Methods: This was a cross-sectional study. Blood samples positive for Plasmodium 
falciparum by light microscopy were transported to the laboratory using TM and the conventional EDTA anticoagulant as control.  
Using 322 Plasmodium falciparum isolates from patients attending outpatient clinic at Chulaimbo sub county hospital, SYBR 
Green 1 in vitro assay IC50 was done against artemether, lumefantrine, dihydroartemisinin and piperaquine. Results: The mean 
IC50 values for drugs were not significantly different in either EDTA or TM samples. Similarly, there was no 
significant correlation between samples which were transported in EDTA except for the Artemisinin derivative 
DHA which had a significant correlation with ART (r = 0.123, p=0.03), LUM (r = 0.1382, p=0.01), and PPQ (r = 
0.1281, p=0.02) and also in TM between DHA and LUM (r=0.1229, p=0.03). Conclusion: Similarity obtained in 
median IC50 between samples in EDTA anticoagulant and TM warrants its continued use. However, DHA significant correlation 
with most of the drugs used, calls for more research to expound on this finding. 
Keywords: Isolates, transport medium, EDTA, susceptibility, inhibitory concentration 50, resistance. 
Introduction 
In Kenya, malaria continues to cause significant morbidity and mortality, and is often a location where drug resistance emerges 
in Africa. The development of P. falciparum resistance to chloroquine diphosphate (CQ), and later sulfadoxine-
pyrimethamine, are well described (Mwai et al., 2009; Khan et al., 1997). This warrants continued in-vitro drug IC50 
monitoring of P. falciparum field isolates, which is becoming more practical and safer, as more  reliable assays like SYBR 
Green I become established, combined with simpler field isolate processing such as “immediate ex-vivo” (IEV) (Akala et al., 
2011). 
SYBR green 1 in vitro technique is the latest technique which is convenient and can be used in a large parasite density and 
produces rapid reproducible results (Rengarajan et al., 2002). Its measure of sensitivity depends on the growth of parasites 
subjected to antimalarials in a medium. Lack of in vitro plasmodial growth has been attributed to; the effects of a markedly 
diminished viability of all parasite populations within the same isolate leading to death of the parasites before reaching the 
laboratory (Basco, 2004), very low starting parasitaemia due to poor survival rates of the parasites from the field (Bacon et al., 
2007), or presence of trace amounts of antimalarial drugs or intake of traditional medicine undetected by urine test (Basco, 2003). 
Low yield of the in vitro assay was also observed in Nigeria, which may have been due to suboptimal storage and transportation 
conditions of parasitized blood, or the presence of traces of the drug in the sample rather than limitations of the technical approach 
(Issaka et al., 2013). To enhance the immediate survival and later growth of these parasites, there is need for a proper transition 
from the natural human host to the artificial medium which will subsequently be used for transportation to the laboratory.  
Apart from the medium which the parasites are exposed to, parasites growth rates sometimes depend on the source of serum used. 
For instance the diet, medication consumed, state of health, and immune status of a donor can inadvertently affect growth rates 
and modify the 50% inhibitory concentration (IC50) results (ofulla et. al., 1994). The presence of trace amounts of antimalarial 
drugs or intake of traditional medicine undetected by urine test for commonly used antimalarial drugs may partially explain why 
some fresh isolates do not grow in vitro (Basco, 2003). Furthermore, serum may contain unknown quantities of drug-binding 
proteins that can skew IC50 values. For maximum plasmodial growth, it is important eliminating all these host immune 
components before test, so as to render maximum growth of the parasites in the antimalarials, thus, making it reliable especially 
for fresh clinical isolates meant for epidemiological studies (Russell et al., 2003).  
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This study was carried out in order to shed light on the use of a transport medium with nutrients which can promote better 
transition and adaptation to enhance prolonged survival and viability of the plasmodium parasites once removed from the human 
host. 
Materials and methods 
Study sites: Chulaimbo sub-county hospital located in Maseno division of Kisumu County in western Kenya. The hospital is 
about 10 kilometers away from the laboratory at Maseno University. 
Participant selection procedure: Patients attending outpatient clinic at Chulaimbo subcounty hospital, who were at least 2 years 
of age and having met the inclusion criteria were invited to participate. Patients with mono infection of P. falciparum parasitaemia 
between 1000 to 200,000 asexual parasites/ul of blood and gave informed consent to participate were included in the study. 
Blood sample collection and preparation: Laboratory staffs at Chulaimbo subcounty hospital were trained on the inclusion and 
exclusion criteria for study participants’.  A total of 4ml venous blood was drawn by a trained phlebotomist from patients who 
gave informed consent to participate in the study. For each participant, 2ml of the blood was collected into a plain vacutainer tube 
with 2ml of the formulated transport medium while the remaining 2ml was drawn into EDTA coated vacutainer tube. Both tubes 
were placed at 40C until transported to the laboratory at the close of the day to begin immediate ex vivo (IEV) drug IC
50
testing as 
described below.  
Laboratory analysis procedures: SYBR Green 1 based in vitro IC50 drug sensitivity was used to test each P. 
falciparum isolate transported in TM and EDTA against artemether (ART), lumefantrine (LU), dihydroartemisinin 
(DHA) and piperaquine (PPQ). The test drugs were obtained from Kenya Medical Research Institute (KEMRI). 
Briefly, the samples (in TM and EDTA) were washed twice using complete medium by centrifugation as a simple pretest 
procedure to remove antimalarial immune plasma, white blood cells, and residual drugs which may be present in the test blood, 
before subjecting it to the drugs. The IC50 results obtained were compared with the IC50 results obtained from samples collected 
using the EDTA coated tubes. 
To prepare the test drugs, solutions at 1mg/ml were prepared in 5ml 100% dimethyl sulfoxide for ART, LU, DHA and 
PPQ. Further dilutions were incomplete RPMI 1640 media to the desired starting concentrations followed by two fold 
serial dilutions to generate 10 concentrations for IC50 testing (Mbaisi et al., 2004). The concentrations ranged from 200 
to 0.0976ng/ml for ART, LU, and DHA while PPQ was 500 to 0.2441ng/ml. The drug solutions were used immediately 
after preparation or stored at -800C for not more than 1 month before use. A successful assay result was defined as 
dose concentration relationship across the 10 drug dilutions for one or all drugs per field isolate. Basic and complete 
RPMI 1640 culture media, the later with glucose and hypoxanthine enrichment, were prepared as described by Johnson 
et al., (2007). P. falciparum isolates processed IEV were placed into assay within 8 hours of phlebotomy, without culture 
adaptation. The samples were first washed in RPMI 1640 by centrifugation at 2500 revolutions per minute for 3 minutes for three 
consecutive times. Blood samples with >1% parasitemia were adjusted to 1% parasitemia at 2% hematocrit using uninfected 
O+ erythrocytes, and those with ≤1% parasitemia were used unadjusted at 2% hematocrit. Transfer of parasite sample and 
antimalarial drug aliquots in complete RPMI 1640 drug aliquots into 96-well microculture plates and addition of lysis buffer 
after 72hours incubation was done as previously described (Johnson et al., 2007). The plates were then placed at room 
temperature in the dark, for 5–15 minutes. Parasite replication inhibition was quantified and the IC50  for each drug 
calculated by an equation generating a sigmoidal concentration response curve (variable slope), with log transformed drug 
concentrations on the X axis and relative fluorescent units (RFUs) on the Y axis (Graph pad Prism for Windows, version 
5.0; Graph pad Software, Inc., San Diego, CA). (Bacon et al., 2007). 
Statistical analysis: Data was analysed using Mann-Whitney test to compare the medians IC50 values of 
antimalarials in EDTA and TM. Pearson correlation coefficient was used to determine the r value which gave the 
possible correlation of the logarithmic values of IC50 between the antimalarials in each EDTA and TM. Data were 
analysed using Graph Pad Prism 5.00 for Windows (Graph Pad Software, San Diego, CA, and Sigma Plot version 10; Systat 
Software, Inc., San Jose, CA). 
Ethical consideration: The study was approved by Jaramogi Oginga Odinga Teaching and Referral Hospital Ethics and 
review committee (Ref. 01713). Written informed consent was obtained from participating adults aged at least 18 years or legal 
guardians for those less than 18 years. 
Results 
A total of 322 P. falciparum field isolates were assayed against four panels of drugs namely ART, LUM, DHA and 
PPQ. Successful assay defined as a concentration-response across the 10 drug concentrations for 1 or more drugs per 
each P. falciparum field isolate, occurred in more than 50% of all the isolates in EDTA and TM. 70% of the assays had 
parasitaemia >0.5%.  18% of the plates gave high relative fluorescent units (RFU) for samples in both groups while 
82% of the plates gave moderate RFU of between 4000-8000 parasites or even lower. However, all the curves 
converged to create IC50 dose response curves. Those whose curves did not converge were excluded from the study. 
Table 1 shows that although not statistically significant, the median IC50 values obtained from 322 samples 
transported using EDTA anticoagulant were higher than those in TM for LUM (5.409 vs 4.007ng/ml, p=0.74), 
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DHA (2.567 vs 1.691ng/ml, p=0.68), and PPQ (7.887 vs 6.911ng/ml, p= 0.82). On the other hand, the median IC50 
was slightly higher in TM than EDTA for ART (4.887 vs 4.275ng/ml, p=0.99). Notably, in both categories, the 
least median IC50 values were experienced by samples treated with DHA while the highest IC50 values were 
experienced with the samples exposed to PPQ. 
Comparison of the mean IC50 values gave no significant different (p>0.05) results for the drugs in either EDTA or 
TM categories except for ART which showed a significant decrease in mean IC50 (23.94ng/ml vs 19.25ng/ml, 
p=0.006) for samples in TM than EDTA. The IC50 ranges for all the drugs were in the upper half of the IC50 range 
as shown in Figure 1. 
Pearson’s correlation coefficient analysis of the antimalarials log IC50 values was perfomed separately for samples 
which were transported in EDTA and TM (Table 2). There was no significant correlation between samples which 
were transported in EDTA for ART and LUM (r=0.04967, p=0.37), ART and PPQ (r=0.0262, p=0.64), and finally 
LUM and PPQ (0.0584, p=0.29), However, significantly high correlations were observed in Artemisinin 
derivatives ART and DHA (r = 0.123, p=0.03), LUM and DHA (r = 0.1382, p=0.01), and DHA and PPQ (r = 
0.1281, p=0.02). Among the samples in the TM, significant correlations were observed in ART and LUM 
(r=0.1260, p=0.02), ART and PPQ (r=0.1382, p<0.001) and finally LUM and DHA (r=0.1229, p=0.03) while the 
rest showed no significant correlation with r values lower than 0.1.  
Discussion 
In vitro drug assays in the field are best performed on fresh isolates immediately after collection (Basco, 2004). It is simpler to 
perform than culture adapted assays (Akala et al., 2011; Bacon et al., 2007) and also reduces concerns on the selection of 
dominant clones and loss of minor subpopulations (Liu et al., 2008) hence consequent misidentification of a population’s 
susceptibility profile (Mbaisi et al., 2004). However, blood samples containing P. falciparum parasites for testing may be stored at 
collection sites for days or transported long distances to the laboratory before cultivation (Akala et al., 2011), a factor which could 
cause failure of growth attributed to a prolonged time between the times when samples were collected and when they were tested 
(Bacon et al., 2007) hence reducing the parasites viability to even zero (Basco, 2004).  
Availability of a medium would provide a proper transition from the natural host to an artificial medium and would keep the 
parasites viable to the laboratory for cultivation. In that regard, this study employed the use of a formulated transport media (TM) 
with an aim of trying to improve on the viability of parasites during transportation to the laboratory for further cultivation. This is 
the first study to report a direct comparison between two anticoagulants, evaluating the possible influence of TM on maintaining 
parasite viability during storage at 4°C against the conventional EDTA anticoagulant. EDTA has the advantages of a lack of 
inhibitory action on DNA allowing the best preservation of cellular components and morphology of blood cells (Reardon et al., 
1993), thus best for hematologic and biochemical investigations (Basco, 2004). Among the assays, the upper half of the IC50 was 
notably higher in our study for all the drugs in both categories, which may reflect greater biological variability among the field 
isolates with the presence of sub populations of drug resistant and sensitive parasites (Jefari et al., 2004). This factor addressed the 
fact that some plates produced assays whose curves did not calculate an IC50 because the points could not converge to create an 
ideal IC50 dose response curve due to the presence of a subpopulation in low proportions (10%), as also evident elsewhere (CO-
EM et al., 2009).  
Patient blood samples usually have very different levels of parasitemia, and most drug assays are sensitive to variation in 
parasitemia. (Liu et al., 2008). Parasitaemia estimation in any in-vitro assay is highly dependent on microscopy therefore, 
variation occurs depending on the expertise of the microscopist in the laboratory. If the starting parasitaemia in an assay is 
mistakably high then much infected parasites would be found in each well of the plate leading to an increase in the absorption of 
drugs, (Ritchie et al., 1996) consequently increasing the IC50 levels obtained (Geary et al., 1990). This explains the high levels of 
RFU when curves were plotted against the drug concentration in the present study. The reverse side, a very low starting 
parasitaemia may lead to a lack of growth and less IC50 values (Bacon et al., 2007). Increasing the number of infected erythrocytes 
lead to higher drug uptake (Basco, 2004) such that there is need for an increased concentration of drugs to inhibit growth when 
numbers of parasites per volume were inoculated (Duraisinngh et al., 1999; Gluzman et al., 1987). A study in Cambodia also 
found that parasitaemia level is inversely proportional to the IC50 values (Suwanna et al., 2013). These previous studies justified 
the high IC50 values obtained with some plates which consequently raised the mean and median IC50 values especially for PPQ in 
the current study for samples in both EDTA and TM since both used the same amount of parasitaemia. 
The DHA was the most active drug with the least median IC50 values (2.567ng/ml and 1.691ng/ml in EDTA and TM respectively) 
and ranges in both EDTA and TM samples which were not significant. This could be attributed by the fact that they are few if any 
reduced susceptibility cases of the drug in the region and generally in Kenya. This is in line with a study conducted at the Kenyan 
coast in which DHA emerged the most active drug (Mwai et al., 2009). Highest IC50 values of 7.887ng/ml in EDTA and 
6.911ng/ml in TM samples obtained by PPQ in our data were unlikely to represent resistance but probably methodological 
variability, since these values were way below the IC50 values from previous studies done in malaria endemic areas (Basco et 
al.,2003; Basco et al., 2007 and Mwai et al., 2009). 
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 In contrast with other studies which have found an IC50 LUM activity of 30nm for more than 95% of isolates (Mayxay et al., 
2007; Parola et al., 2007; Paradines et al., 2006), our study generated only 24% and 20% from samples in EDTA and TM 
respectively, a clear indication that the activity of the drug which is used as a partner to ART for treatment of uncomplicated 
malaria cases remains high in the region. Encouragingly, our ART IC50 data which were 4.27nm and 4.88nm in EDTA and TM 
respectively, were comparable with those found earlier for clinical isolates collected in Cameroon and other African countries 
where the IC50 values ranged between 3.46nm and 5.66nm (Basco and LeBras, 1993; Basco and Ringwald, 2003 and Issaka et al., 
2013) 
The inoculum size used in in vitro testing influences the measured in vitro susceptibility to antimalarials, therefore resistance can 
be overestimated when inoculum effects are not considered. On the other hand, occurrences of cross resistance between 
antimalarials can also be falsely determined in some cases (Duraisinngh et al., 1999). Positive correlation was observed between 
DHA and all the tested drugs (ART, LUM and PPQ) for samples in EDTA, unlike the same samples in TM where DHA had 
statistically significant correlation of r=0.1229 (p=0.02) with LUM only while others were not significant. The variation observed 
in cross resistance of DHA in the samples in EDTA and TM would have been attributed by the inoculum effect. However, further 
research need to be conducted to rule out the possible cross resistance between these drugs in the region. A study at the coast in 
Kenya found a positive correlation between DHA and LUM, as well as PPQ and LUM (Mwai et al., 1999), in line with the results 
of the current study.  
Conclusion 
Results from this study suggests that the formulated transport medium (TM) holds promise for future use having shown similar 
IC50 results with no significant difference with the samples which were transported in EDTA anticoagulant tubes. Variations in the 
positive correlations experienced by DHA indicate possible cross resistance between the drugs which need further research to 
elucidate on the finding. 
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Table 1: Drug susceptibility testing of Plasmodium falciparum isolates in EDTA and TM against a 
panel of antimalarials 
 Median IC50 (ng/ml) for P. falciparum isolates transported 
in: 
 
Drugs EDTA TM p-value 
Artemether (ART) 4.275 4.887 0.9873 
Lumefatrine (LUM) 5.409 4.007 0.7448 
Diydroartemisinin (DHA) 2.567 1.691 0.6839 
Piperaquine (PPQ) 7.887 6.911 0.8153 
Comparison of the medians using Mann - whitney test 
Key: TM= Transport medium, p = significance level of the test
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Table 2: Correlation of in vitro responses of antimalarial drugs against field isolates of P. falciparum 
in EDTA and TM 
 In vitro correlation of drugs against P. falciparum isolates transported in: 
 EDTA TM 
Drug pairs Correlation 
coefficient (r) 
p-value Correlation 
coefficient (r) 
p-value 
ART - LUM 0.04967 0.3699 0.1260 0.0225 
ART - DHA 0.123 0.0259 0.09014 0.1032 
ART - PPQ 0.0262 0.6364 0.1834 0.0008 
LUM - DHA 0.1382 0.0122 0.1229 0.0261 
LUM - PPQ 0.0584 0.2916 0.0758 0.1709 
DHA -  PPQ 0.1281 0.0203 0.0372 0.5024 
Correlation of the drug pairs using pearsons correlation coefficient 
Key: ART = Artemether, LUM = Lumefantrine, DHA = Dihydroartemisinin, PPQ  
=Piperaquine, p = significance level of the test, r = Pearson’s correlation coefficient of log IC50 
values.TM= Transport medium 
 
Figure 1: In vitro activities of ART, LUM, DHA and PPQ against P. falciparum field isolates transported in 
EDTA and TM 
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